Comparison of the efficacy of strontium-89 chloride in treating bone metastasis of lung, breast, and prostate cancers
| Autor: | Xiaojuan Ye, Da Sun, Cen Lou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Lung Neoplasms Biopsy Bone Neoplasms Breast Neoplasms Small-cell carcinoma Multimodal Imaging lcsh:RC254-282 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Bone pain Lung cancer Aged Aged 80 and over Lung business.industry Bone metastasis Prostatic Neoplasms strontium-89 chloride General Medicine Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lung cancer medicine.anatomical_structure Treatment Outcome Strontium 030220 oncology & carcinogenesis Adenocarcinoma Female medicine.symptom Radiopharmaceuticals business |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 14, Iss 8, Pp 36-40 (2018) |
| ISSN: | 1998-4138 0973-1482 |
| Popis: | Objective: The aim of this study was to comparatively evaluate the efficacy of strontium-89 chloride (89 SrCl2) in treating bone metastasis-associated pain in patients with lung, breast, or prostate cancer. Materials and Methods: The 126 patients with lung cancer included 88, 16, 15, 4, and 3 patients with adenocarcinoma, squamous cell carcinoma, nonsmall cell carcinoma, mixed carcinoma, and small cell carcinoma, respectively, and the control group consisted of patients with breast (71 patients) or prostate cancer (49 patients) who underwent 89 SrCl2 treatment during the same period. The treatment dose of 89 SrCl2 was 2.22 MBq/kg. Results: The efficacy rate of treatment in the lung cancer group was 75.4%, compared to 95.0% in the control group. Approximately 67% of patients with lung cancer and bone metastases and 47% of control patients exhibited mild-to-moderate reductions of leukocyte and platelet counts 4 weeks after 89 SrCl2 treatment. Conclusions: 89 SrCl2 can safely and effectively relieve bone pain caused by bone metastasis from lung cancer. However, its efficacy was lower in patients with lung cancer with bone metastasis than in those with breast or prostate cancer with bone metastasis, and its effects on the peripheral hemogram were also significantly stronger in the lung cancer group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |